Acoramidis has potential for treating transthyretin amyloid cardiomyopathy, according to a trial.

Published Date: 30 Aug 2023

Acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in comparison to placebo, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Year in Review: Chronic Lymphocytic Leukemia

2.

According to a study, white Americans are overdiagnosing melanoma at an alarming rate.

3.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

4.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

5.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot